Zobrazeno 1 - 10
of 504
pro vyhledávání: '"John, Kuruvilla"'
Autor:
Ronan Foley, John Kuruvilla
Publikováno v:
Oncology and Therapy, Vol 12, Iss 2, Pp 239-245 (2024)
Abstract Chimeric antigen receptor T cell (CAR-T) therapies targeting the CD19 antigen have been associated with high and durable response rates in patients with diffuse large B cell lymphoma (DLBCL). CAR-T cell therapies are commonly administered in
Externí odkaz:
https://doaj.org/article/3049620d8bad476589d264379dd4940d
Publikováno v:
HemaSphere, Vol 8, Iss 8, Pp n/a-n/a (2024)
Abstract CD19‐directed autologous chimeric antigen receptor T cell (CAR‐T) therapy has transformed the management of relapsed/refractory (R/R) large B cell lymphoma (LBCL). Initially approved in the third line and beyond setting, CAR‐T is now s
Externí odkaz:
https://doaj.org/article/fa8dce07de684230b7c7956c73bd0448
Publikováno v:
In Atmospheric Pollution Research October 2024
Autor:
Esmail M. Al-Ezzi, Amer Zahralliyali, Aaron R. Hansen, Robert J. Hamilton, Michael Crump, John Kuruvilla, Lori Wood, Lucia Nappi, Christian K. Kollmannsberger, Scott A. North, Eric Winquist, Denis Soulières, Sebastien J. Hotte, Di Maria Jiang
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6166-6176 (2023)
Background: Although metastatic germ cell tumor (GCT) is highly curable with initial cisplatin-based chemotherapy (CT), 20–30% of patients relapse. Salvage CT options include conventional (CDCT) and high dose chemotherapy (HDCT), however definitive
Externí odkaz:
https://doaj.org/article/cdf6575c6dd6426a9ccb2edad31d8e08
Autor:
John Kuruvilla, Emmanuel M. Ewara, Julia Elia-Pacitti, Ryan Ng, Maria Eberg, Atif Kukaswadia, Arushi Sharma
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 4663-4676 (2023)
Background: Many patients with advanced follicular lymphoma (FL) and marginal zone lymphoma (MZL) relapse after first-line chemotherapy. Objective: To examine healthcare resource utilization (HCRU) and cost, treatment patterns, progression, and survi
Externí odkaz:
https://doaj.org/article/23482e06a567402e8638f4a656a8694c
Autor:
Nathalie Johnson, David Lavie, Peter Borchmann, Gareth Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman
Publikováno v:
HemaSphere, Vol 7, p e0274602 (2023)
Externí odkaz:
https://doaj.org/article/a8737852cae34698a0c1cb539063a54a
Autor:
Laurie H. Sehn, Nancy L. Bartlett, Matthew Matasar, Stephen J. Schuster, Sarit Assouline, John Kuruvilla, Mazyar Shadman, Chan Cheah, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael Wei, Shen Yin, Iris To, Nan Hu, Juliana Min, Elicia Penuel, Anton Belousov, Alexandre Coimbra, Skander Jemaa, Brendan Bender, David Turner, L. Elizabeth Budde
Publikováno v:
HemaSphere, Vol 7, p e36694eb (2023)
Externí odkaz:
https://doaj.org/article/0df5a358399145da83d67731e87be8a3
Autor:
Loretta J. Nastoupil, John Kuruvilla, Julio C. Chavez, Fontanet Bijou, Thomas E. Witzig, Armando Santoro, Ian W. Flinn, Carola Boccomini, Vaishalee P. Kenkre, Paolo Corradini, Iris Isufi, David J. Andorsky, Leonard M. Klein, Daniel R. Greenwald, Randeep Sangha, Frank Shen, Patrick Hagner, Yan Li, Juergen Dobmeyer, Nian Gong, Shailaja Uttamsingh, Michael Pourdehnad, Vincent Ribrag
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 394-405 (2022)
Abstract The multicenter, phase Ib CC‐122‐DLBCL‐001 dose‐expansion study (NCT02031419) explored the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC‐122) plus rituximab in patients with relapsed/refractory (R/R) diffuse large B‐c
Externí odkaz:
https://doaj.org/article/893d9f4d49df48ae90782ee3c1a4ed6c
Autor:
Guillaume Cartron, Christopher P. Fox, Fei Fei Liu, Ana Kostic, Jens Hasskarl, Daniel Li, Ashley Bonner, Yixie Zhang, David G. Maloney, John Kuruvilla
Publikováno v:
Experimental Hematology & Oncology, Vol 11, Iss 1, Pp 1-16 (2022)
Abstract Background There are no head-to-head clinical studies comparing chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory aggressive large B-cell lymphomas. Naive, indirect comparisons may be inappropriate,
Externí odkaz:
https://doaj.org/article/698d9b2a89f14a2195e893f2e8c21cfc
Autor:
Vincent Ribrag, Julio C. Chavez, Carola Boccomini, Jason Kaplan, Jason C. Chandler, Armando Santoro, Paolo Corradini, Ian W. Flinn, Ranjana Advani, Philippe A. Cassier, Randeep Sangha, Vaishalee P. Kenkre, Iris Isufi, Shailaja Uttamsingh, Patrick R. Hagner, Anita K. Gandhi, Frank Shen, Sophie Michelliza, Harald Haeske, Kristen Hege, Michael Pourdehnad, John Kuruvilla
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 139-153 (2022)
Abstract There is a need for additional treatment options for patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) who do not benefit from available therapies. We examined combinations of the cereblon E3 ligase modulator (CELM
Externí odkaz:
https://doaj.org/article/96c484da7911405ebd05aa9e00d581f2